GLP-1 receptor agonists significantly reduce weight and fat while preserving lean tissue
Updated
Updated · Nature.com · Apr 25
GLP-1 receptor agonists significantly reduce weight and fat while preserving lean tissue
7 articles · Updated · Nature.com · Apr 25
A meta-analysis of 24 studies with 1,032 overweight or obese adults found GLP-1 RAs reduced body weight by 9% at 3 months, 5% at 6 months, and 4% at 12 months.
Fat mass and visceral adipose tissue declined substantially, while reductions in lean body mass were modest, indicating 'quality' weight loss. Efficacy varied between agents, with semaglutide, liraglutide, and exenatide showing comparable effects.
GLP-1 RAs also improved cardiometabolic parameters and were effective in both diabetic and non-diabetic populations. Individualized treatment strategies, alongside nutrition and exercise, are recommended to optimize long-term outcomes and preserve muscle mass.
Beyond weight loss, could these drugs be the next treatment for addiction and Alzheimer's?
With an oral pill now available, will weight-loss drugs finally become affordable?
Is lifelong medication the only way to manage obesity in the modern world?
Are next-generation drugs being developed that can melt fat without touching muscle?
Are popular weight-loss drugs secretly aging your muscles by a decade?
Could a simple genetic test soon predict if Ozempic will work for you?
Optimizing Obesity Treatment in 2026: Maximizing Fat Loss While Preserving Functional Muscle with GLP-1RAs and Combination Therapies
Overview
GLP-1 receptor agonists (GLP-1RAs) promote weight loss mainly by reducing fat mass while preserving muscle function. This selective fat loss improves body composition, with fat-to-body weight ratios decreasing and lean mass ratios rising, even as muscle strength remains stable. Combination therapies, like semaglutide with bimagrumab, enhance these effects by maximizing fat loss and minimizing muscle loss. Biological mechanisms include appetite suppression, increased fat breakdown, reduced inflammation, and improved muscle insulin sensitivity, which together protect muscle during calorie deficits. However, lean mass loss still occurs, especially with some agents, posing risks for vulnerable groups. Integrating resistance exercise and adequate protein intake is essential to maintain muscle and optimize treatment outcomes.